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MaBACKGROUND In a signiﬁcant update, the 2013 American College of Cardiology/American Heart Association (ACC/AHA)
cholesterol guidelines recommend ﬁxed-dose statin therapy for those at risk and do not recommend nonstatin therapies or
treatment to target low-density lipoprotein cholesterol (LDL-C) levels, limiting the need for repeated LDL-C testing.
OBJECTIVES The goal of this study was to examine the impact of the 2013 ACC/AHA cholesterol guidelines on current
U.S. cardiovascular practice.
METHODS Using the NCDR PINNACLE (National Cardiovascular Data Registry Practice Innovation and Clinical Excel-
lence) registry data from 2008 to 2012, we assessed current practice patterns as a function of the 2013 cholesterol
guidelines. Lipid-lowering therapies and LDL-C testing patterns by patient risk group (atherosclerotic cardiovascular
disease [ASCVD], diabetes, LDL-C $190 mg/dl, or an estimated 10-year ASCVD risk $7.5%) were described.
RESULTS Among a cohort of 1,174,545 patients, 1,129,205 (96.1%) were statin-eligible (91.2% ASCVD, 6.6% diabetes,
0.3% off-treatment LDL-C $190 mg/dl, 1.9% estimated 10-year ASCVD risk $7.5%). There were 377,311 patients
(32.4%) not receiving statin therapy and 259,143 (22.6%) receiving nonstatin therapies. During the study period, 20.8%
of patients had 2 or more LDL-C assessments, and 7.0% had more than 4.
CONCLUSIONS In U.S. cardiovascular practices, 32.4% of statin-eligible patients, as deﬁned by the 2013 ACC/AHA choles-
terol guidelines, were not currently receiving statins. In addition, 22.6%were receiving nonstatin lipid-lowering therapies and
20.8% had repeated LDL-C testing. Achieving concordance with the new cholesterol guidelines in patients treated in U.S.
cardiovascular practiceswould result in signiﬁcant increases in statin use, aswell as signiﬁcant reductions in nonstatin therapies
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ABBR EV I A T I ON S
AND ACRONYMS
ACC = American College
of Cardiology
AHA = American
Heart Association
ASCVD = atherosclerotic
cardiovascular disease
ATP = Adult Treatment Panel
LDL-C = low-density
lipoprotein cholesterol
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2184I n 2013, at the request of the NationalHeart, Lung, and Blood Institute ofthe National Institutes of Health, the
American College of Cardiology (ACC) and
American Heart Association (AHA) updated
the guidelines on the treatment of blood
cholesterol to reduce atherosclerotic cardio-
vascular risk in adults (1–3). This update was
a signiﬁcant departure from the previous
Third Report of the National Cholesterol
Education ProgramExpert Panel onDetection,Evaluation, and Treatment of High Blood Cholesterol
in Adults (Adult Treatment Panel [ATP] III) guidelines
(4), and focused primarily on randomized controlled
trials, consistent with the recent recommendations
by the Institute ofMedicine for guideline development
(5,6). The new guidelines redeﬁned patient popula-
tions for treatment, targeting those with conﬁrmed
atherosclerotic cardiovascular disease (ASCVD), dia-
betes, native low-density lipoprotein cholesterol
(LDL-C) levels $190 mg/dl, or 10-year cardiovascular
risk $7.5%. The new guidelines recommended a
“treat to risk” strategy using ﬁxed-dose statin medi-
cations, rather than the previous “treat to LDL-C
target” strategy; did not recommend use of nonsta-
tin therapies; and did not recommend treatment to
target LDL-C lipid levels, thus rendering repeated
on-treatment testing unnecessary.SEE PAGE 2193The potential impact of the new guidelines on
current U.S. cardiovascular practice is unknown.
Because cardiologists typically treat patients at the
highest risk for cardiac events, optimizing cholesterol
management in light of these new guidelines would
be expected to have a signiﬁcant impact. Although
there has been work published on the population
impact of these new guidelines (7), important ques-
tions remain unanswered. In particular, little is
known about current lipid-lowering therapies and
LDL-C testing patterns; this knowledge would help
quantify expected shifts in care and subsequent im-
plications for statin use, nonstatin use, and LDL-C
testing among risk groups.
Accordingly, we examined the implications of the
2013 ACC/AHA cholesterol guidelines on current
lipid-lowering therapy and testing patterns in
contemporary cardiology practices using data from
the NCDR PINNACLE (National Cardiovascular Data
Registry Practice Innovation and Clinical Excellence).
The PINNACLE registry collects continuous, real-
time, clinical information on all patients treated
in participating outpatient cardiology practices in
the Unites States. As such, current lipid-loweringtherapy and LDL-C testing patterns can be assessed,
and the shifts expected under the new guidelines can
be predicted. This study sought to determine the
prevalence in the PINNACLE registry of patients
meeting eligibility criteria for statin therapy under
the new guidelines and to assess their current therapy
and LDL-C testing patterns. Using registry data from
2008 to 2012, patients were classiﬁed by risk group
(ASCVD, diabetes, LDL-C $190 mg/dl, or an estimated
10-year ASCVD risk $7.5%) and lipid-lowering thera-
pies and LDL-C testing patterns were described.
METHODS
DATA SOURCE. The NCDR PINNACLE served as the
study data source. Cardiology practices voluntarily
participate in and submit data to PINNACLE as part
of a national ofﬁce-based cardiovascular quality
improvement program (8). Data are collected on all
patients with hypertension, coronary artery disease,
heart failure, and/or atrial ﬁbrillation. The data are
collected at the point of care through a validated
electronic medical record mapping algorithm de-
signed to comprehensively capture required data
elements or, in rare cases when electronic health re-
cords are not in use, a paper chart abstraction form.
These data elements include demographics, insur-
ance status, and detailed clinical information in-
cluding symptoms, medical conditions, vital signs,
medications, and laboratory values. Registry data
quality assurance is maintained through rigorous data
deﬁnitions, standard data collection and trans-
mission, and periodic data quality checks (9,10).
STUDY POPULATION. All patients aged 18 years
or older with clinical encounters in the PINNACLE
registry (version 1.2) between January 1, 2008, and
December 31, 2012, were identiﬁed. Patients with
insufﬁcient data to determine their risk group, as
outlined in the 2013 cholesterol guidelines, were
excluded. Patients were then categorized into 5
mutually exclusive risk groups on the basis of the 2013
cholesterol guidelines: ASCVD; diabetes (without
ASCVD); off-treatment LDL-C $190 mg/dl (without
ASCVD or diabetes); 10-year ASCVD risk $7.5%
(without ASCVD, diabetes, or off-treatment LDL-C
$190 mg/dl); or no risk criteria. ASCVD criteria
included: medical record documentation of coronary
artery disease; peripheral arterial disease; previous
stroke or transient ischemic attack; unstable angina;
stable angina; myocardial infarction; coronary artery
bypass grafting; and/or percutaneous coronary inter-
vention. Next, patients without evidence of ASCVD,
ages 40 to 75 years, and with medical record docu-
mentation of diabetes were identiﬁed. Patients
PINNACLE registry patients
between 2008 and 2012
(n=1,711,326)
Final study cohort
(n=1,174,545)
Excluded (n=536,781)
Age <18 yrs (n=6,561)
Missing LDL-C values (n=465,234)
Missing race (n=50,431)
Missing tobacco status (n=4,704)
Other missing data (n=9,851)





FIGURE 1 Study Cohort Creation
Review of all PINNACLE (Practice Innovation and Clinical Excellence) registry patients
between 2008 and 2012, as well as the ﬁnal study cohort. LDL-C ¼ low-density lipo-
protein cholesterol.
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2185without evidence of ASCVD or diabetes, on no lipid-
lowering therapies, and with $1 LDL-C value
$190 mg/dl were then identiﬁed. Patients without
ASCVD or diabetes or an off-treatment LDL-C $190
mg/dl and ages 40 to 75 years were next identiﬁed and
had their estimated 10-year ASCVD risk calculated
using the pooled risk calculator referenced in the 2013
cholesterol guidelines (1). Those with an estimated 10-
year risk $7.5% were included in the fourth group.
Finally, those patients who did not meet the criteria
for any of the 4 risk groups were classiﬁed as “no risk
criteria.” To determine the ﬁnal risk group classiﬁca-
tion for patients with multiple risk group qualiﬁca-
tions over time, all clinic visits recorded in PINNACLE
for each patient were examined for each risk group
classiﬁcation in a sequential, hierarchical fashion. For
example, if 2 years after his or her diabetes diagnosis,
a diabetic patient were noted to develop ASCVD, that
patient would be placed in the ASCVD group for
analysis. If none of the risk group criteria were met by
the ﬁnal recorded visit in PINNACLE, then that patient
was placed in the “no risk criteria” group. The visit
where the ﬁnal risk group classiﬁcation criteria were
met was designated as the index visit.
The PINNACLE registry included data on 1,711,326
patients treated in 111 U.S. cardiovascular practice
clinics from 2008 to 2012 (Figure 1). In total, 536,781
patients were excluded from the study cohort: 6,561
patients were excluded because they were <18 years
of age; and 530,220 patients were excluded because
they could not be mapped to 1 of the 5 patient groups
(465,234 [87.7%] were excluded due to missing LDL-C
values, 50,431 [9.5%] due to missing race, 4,704
[0.9%]) due to missing tobacco use, and 9,851 [1.9%]
for other miscellaneous causes). The ﬁnal study
cohort comprised 1,174,545 patients.
CLINICAL OUTCOMES AND CHARACTERISTICS. The
primary study outcomes were lipid-lowering therapies
and LDL-C testing patterns among the 5 patient risk
groups. To determine therapy patterns, the 5 patient
risk groups outlined were stratiﬁed into 4 categories:
those receiving no lipid-lowering therapy; those re-
ceiving nonstatin lipid-lowering therapies only; those
receiving statins as their sole lipid-lowering therapy;
and those receiving both statin and nonstatin thera-
pies. Examples of nonstatin lipid-lowering therapies
include ﬁbrates, cholestyramine, and nicotinic acid.
Receipt of therapy was determined by examining all
clinic visits recorded after the index visit, as we have
already deﬁned. For example, if statin therapy was
noted at any visit after the index visit and nonstatin
therapy was never noted at any visit after the index
visit, then the patient was classiﬁed in the statin
therapy–only group. We also excluded patients withdocumented reasons for nonprescription of lipid-
lowering therapies from our analyses to ensure
that our calculations represented prescription rates
among eligible patients. Speciﬁcally, patients with
documented nonprescription reasons for statins,
nonstatins, or both were excluded from the no lipid-
lowering therapy and both statin and nonstatin
therapy groups. Patients with nonprescription rea-
sons for statins only were excluded from the statin-
only group. Patients with nonprescription reasons
for nonstatins only were excluded from the non-
statin-only group.
To determine LDL-C testing patterns, we collected
the number of LDL-C assessments obtained per
patient, both overall and by each patient group. All
assessments collected at the index visit and those at
subsequent visits were counted. For those patients in
the “no risk criteria” group, all LDL-C assessments
collected at any visit recorded in PINNACLE were
counted. For those patients with >1 assessment on a
particular day, only 1 was tabulated, as this likely
indicated double counting.
STATISTICAL ANALYSIS. Descriptive analyses were
performed for the 5 patient risk groups. Demographic,
clinical, and medication characteristics were des-
cribed and compared. Variables were compared using
1-way analyses of variances. Adjustments for multiple
comparisons were not made. Next, among those
patients with an indication for statin therapy under
TABLE 1
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2186the new guidelines, those receiving no therapies,
those receiving nonstatin lipid-lowering therapies,
those receiving statin therapies, and those receiving
both statin and nonstatin therapies were calculated.
Therapy rates by patient risk group were also calcu-
lated. Finally, LDL-C assessments were calculated
and grouped by ascending number.
Several secondary analyses were conducted to
support or clarify our primary analyses. First, we
excluded all patients with heart failure symptoms of
New York Heart Association functional class III or IV
severity because the guidelines do not recommend
statin therapy in this patient population (1). Second,
we restricted the categorization of those in the
10-year estimated ASCVD risk to those with a risk
$10% to address concerns about the potential over-
estimation of risk of the pooled risk calculator (11).
Third, we expanded the categorization of those in the
10-year estimated ASCVD risk group to those with a
risk $5% because the guidelines indicate that statin
therapy confers a net absolute beneﬁt in this group of
patients, thus warranting its consideration. Fourth,Characteristics of PINNACLE Patient Risk Groups
Overall
(N ¼ 1,174,545)
ASCVD
(n ¼ 1,029,633)
DM
(n ¼ 75,04
hics
65.2  14.0 65.7  14.1 59.7  9.
639,150 (54.5) 575,932 (56.0) 33,505 (44.
535,096 (88.7) 444,820 (89.3) 30,857 (81.
e
36,655 (3.6) 32,060 (3.5) 2,297 (3.8
e 642,231 (62.6) 562,316 (62.3) 39,225 (64.
are 306,737 (29.9) 275,242 (30.5) 14,906 (24.
aid 22,546 (2.2) 19,289 (2.1) 2,426 (4.0
17,180 (1.7) 14,286 (1.6) 1,764 (2.9
tory
898,488 (76.5) 898,488 (87.3) 0
s MI 339,667 (28.9) 339,667 (33.0) 0
y revascularization 290,266 (24.7) 290,266 (28.2) 0
e angina 18,587 (1.6) 18,587 (1.8) 0
ngina 98,556 (8.4) 98,556 (9.6) 0
263,005 (22.4) 263,005 (25.5) 0
153,891 (13.1) 153,891 (14.9) 0
914,158 (77.8) 797,936 (77.5) 63,801 (85.
338,411 (28.8) 260,190 (25.3) 75,046 (100
emia 783,399 (66.7) 682,115 (66.2) 49,033 (65.
or current tobacco use 852,508 (63.8) 769,449 (65.8) 47,991 (54.
30.0  6.7 29.7  6.6 34.0  7.
223,759 (19.1) 194,486 (18.9) 11,225 (15.0
VD risk 18.8  17.5 20.6  17.6 16.2  11.
ean  SD or n (%).
atherosclerosis cardiovascular disease; BMI ¼ body mass index; CAD ¼ coronary artery disea
n; LDL ¼ low-density lipoprotein; MI ¼ myocardial infarction; PAD ¼ peripheral artery diseawe measured LDL-C levels <100 mg/dl and <70 mg/dl
among those patients without any lipid-lowering
therapies because providers may have justiﬁably
elected to not prescribe lipid-lowering therapies
for these patients, in line with ATP-3 guidelines.
All analyses were performed with SAS (version 9.3,
SAS Institute, Cary, North Carolina).
RESULTS
PATIENT RISK GROUPS AND CHARACTERISTICS. In
the study cohort of 1,174,545 patients, 1,129,205
(96.1%) patients met criteria for statin therapy:
1,029,633 (91.2%) patients had ASCVD; 75,046 (6.6%)
were diabetic patients without ASCVD; 3,176 (0.3%)
had an off-treatment LDL-C $190 mg/dl without
ASCVD or diabetes; and 21,350 (1.9%) had an esti-
mated 10-year ASCVD risk $7.5% without ASCVD,
diabetes, or LDL $190 mg/dl. Demographic and clin-
ical characteristics of each patient group are listed in
Table 1. In general, more men than women qualiﬁed
for the ASCVD or estimated 10-year ASCVD risk $7.5%6)
LDL $190 mg/dl
(n ¼ 3,176)
10-Yr CVD Risk
$7.5%
(n ¼ 21,350)
No Risk
Criteria
(n ¼ 45,340) p Value
3 58.6  14.0 66.1  6.7 61.8  17.9 <0.001
7) 1,068 (33.7) 12,769 (59.8) 15,876 (35.0) <0.001
1) 1,554 (86.9) 18,994 (89.0) 38,871 (89.1) <0.001
) 149 (5.4) 515 (2.7) 1,634 (4.1) <0.001
7) 1,855 (67.1) 11,621 (62.0) 27,214 (68.0) <0.001
6) 619 (22.4) 6,285 (33.5) 9,685 (24.2) <0.001
) 64 (2.3) 157 (0.8) 610 (1.5) <0.001
) 77 (2.8) 161 (0.9) 892 (2.2) <0.001
0 0 0 <0.001
0 0 0 <0.001
0 0 0 <0.001
0 0 0 <0.001
0 0 0 <0.001
0 0 0 <0.001
0 0 0 <0.001
0) 2,114 (66.6) 16,968 (79.5) 33,339 (73.5) <0.001
.0) 90 (2.8) 0 3,085 (6.8) <0.001
3) 2,982 (93.9) 16,600 (77.8) 32,669 (72.1) <0.001
6) 1,666 (44.5) 12,528 (58.7) 20,874 (44.5) <0.001
8 29.5  5.9 29.9  6.2 29.2  6.9 <0.001
) 542 (17.1) 4,561 (21.4) 12,945 (28.6) <0.001
8 12.5  13.8 13.8  5.8 15.6  21.2 <0.001
se; CVD ¼ cardiovascular disease; DM ¼ diabetes mellitus; HF ¼ heart failure; HTN ¼
se; PINNACLE ¼ Practice Innovation and Clinical Excellence.
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FIGURE 2 Lipid-Lowering Therapies, Overall and by Patient Risk Group
Display of lipid-lowering therapies by patient risk group. Percentages total >100% due
to differing contraindication number per group. Refer to the methods section for further
details. ASCVD ¼ atherosclerotic cardiovascular disease; CVD ¼ cardiovascular disease;
DM ¼ diabetes mellitus; LDL ¼ low-density lipoprotein.
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FIGURE 3 LDL-C Assessments
Display of LDL-C assessments, overall and by patient risk group. Abbreviations as in
Figures 1 and 2.
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2187risk groups, whereas more women than men qualiﬁed
for the diabetes, LDL-C $190 mg/dl, or no risk criteria
risk groups. Among the ASCVD risk group, 25.3% had
diabetes. The median estimated 10-year ASCVD event
risk was 20.6% for the ASCVD group, 16.2% for the
diabetes group, 12.5% for the LDL group, 13.8% for the
estimated risk $7.5% group, and 15.6% for the no risk
criteria group (the median score is 15.6% because, in
line with guideline recommendations, patients over
75 years of age are not included in the estimated
risk $7.5% group).
TREATMENT CATEGORIES BY PATIENT GROUP.
Patients’ lipid-lowering therapies were assessed, both
overall and by risk group. As described in the
methods section, to determine rates of therapy use
among eligible patients, we excluded patients with
contraindications to lipid-lowering therapies. Over-
all, 341,669 eligible patients (29.3%) were not re-
ceiving any lipid-lowering therapy, 35,642 (3.1%)
were receiving nonstatin therapies, 563,685 (48.7%)
were receiving statin therapies, and 223,501 (19.5%)
were receiving both statin and nonstatin therapies
(Figure 2). Treatment patterns by patient risk group
were also assessed. Among the ASCVD risk group,
285,211 eligible patients (27.9%) were not receiving
any lipid-lowering therapy, 28,887 (2.9%) were re-
ceiving nonstatin therapies, 506,009 (49.9%) were
receiving statin therapies, and 200,789 (20.0%) were
receiving both statin and nonstatin therapies. Among
the diabetic risk group, 26,827 eligible patients
(35.9%) were not receiving any lipid-lowering ther-
apy, 3,540 (4.7%) were receiving nonstatin therapies,
32,392 (43.5%) were receiving statin therapies, and
11,927 (16.1%) were receiving both statin and non-
statin therapies. Among the off-treatment LDL-C
$190 mg/dl risk group, 916 eligible patients (29.3%)
were not receiving any lipid-lowering therapy, 194
(6.2%) were receiving nonstatin therapies, 1,384
(45.1%) were receiving statin therapies, and 630
(20.5%) were receiving both statin and nonstatin
therapies. Among the estimated 10-year ASCVD
risk $7.5% risk group, 7,491 eligible patients (35.5%)
were not receiving any lipid-lowering therapy, 1,092
(5.2%) were receiving nonstatin therapies, 8,699
(41.5%) were receiving statin therapies, and 3,799
(18.2%) were receiving both statin and nonstatin
therapies. Among the no risk criteria group, 21,224
eligible patients (47.5%) were not receiving any lipid-
lowering therapy, 1,929 (4.3%) were receiving non-
statin therapies, 15,201 (34.2%) were receiving statin
therapies, and 6,356 (14.4%) were receiving both
statin and nonstatin therapies.
LDL-C TESTING PATTERNS BY PATIENT GROUP.
LDL-C assessments were calculated, both overalland by patient group (Figure 3). Overall, 594,771
patients (50.6%) had no assessments, 335,233
(28.5%) had 1 assessment, and the remaining
244,541 (20.8%) had $2 assessments. Of the 244,541
patients with $2 assessments, 82,037 (7.0%) had >4
assessments. LDL-C assessments by patient risk
group were also calculated. Among the ASCVD risk
group, 540,937 patients (52.5%) had no assessments,
267,686 (26.0%) had 1 assessment, and the remain-
ing 221,010 (21.5%) had $2 assessments. Among the
diabetic group, 53,500 patients (71.3%) had no as-
sessments, 16,462 (21.9%) had 1 assessment, and the
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FIGURE 4 Lipid-Lowering Therapies, Excluding HF NYHA Functional Class III to IV
Lipid-lowering therapies displayed overall and by patient risk group, excluding heart failure
(HF) New York Heart Association (NYHA) functional class III to IV. Abbreviations as in
Figure 2.
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2188remaining 5,084 (6.8%) had $2 assessments. Among
the off-treatment LDL $190 mg/dl group, 46 pa-
tients (1.4%) had no assessments, 2,327 (73.3%) had
1 assessment, and the remaining 803 (25.3%) had $2
assessments. Among the estimated 10-year ASCVD
risk $7.5% group, 152 patients (0.7%) had no as-
sessments, 15,759 (73.8%) had 1 assessment, and the
remaining 5,439 (25.5%) had $2 assessments.
Among the no risk criteria group, 136 patients (0.3%)
had no assessments, 32,999 (72.8%) had 1 assess-
ment, and the remaining 12,205 (26.9%) had $2
assessments.CVD DM LDL ≥190 mg/dl 10-yr CVD
Risk ≥10%
No Risk
Criteria
14
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pies displayed overall and by patient risk group, using an estimated
Abbreviations as in Figure 2.EXCLUSION OF PATIENTS WITH NEW YORK HEART
ASSOCIATION FUNCTIONAL CLASS III TO IV. In our
study cohort, 14,478 patients (1.2%) had heart failure
symptoms of New York Heart Association functional
class III to IV severity. Lipid-lowering therapy rates
did not signiﬁcantly vary after their exclusion from
the cohort (Figure 4). There were 338,005 eligible pa-
tients (29.4%) not receiving any lipid-lowering ther-
apy, 35,185 (3.1%) receiving nonstatin therapies,
558,484 (48.7%) receiving statin therapies, and
218,537 (19.3%) receiving both statin and nonstatin
therapies.
ESTIMATED 10-YEAR ASCVD RISK ‡10% THRESHOLD.
When we used an estimated 10-year ASCVD risk $10%
threshold for the primary prevention risk calculation,
5,344 (0.5%) of our cohort moved from the estimated
10-year ASCVD risk $7.5% prevention group to the no
risk criteria group. The rates of lipid-lowering thera-
pies among these groups did not signiﬁcantly change
from the primary analysis (Figure 5). Among the
estimated 10-year ASCVD risk $10% group, 5,473
eligible patients (34.7%) were not receiving any lipid-
lowering therapy, 833 (5.3%) were receiving non-
statin therapies, 6,574 (41.8%) were receiving statin
therapies, and 2,904 (18.6%) were receiving both
statin and nonstatin therapies. Among the no risk
criteria group, 23,164 eligible patients (46.4%) were
not receiving any lipid-lowering therapy, 2,183 (4.4%)
were receiving nonstatin therapies, 17,277 (34.8%)
were receiving statin therapies, and 7,290 (14.8%)
were receiving both statin and nonstatin therapies.
ESTIMATED 10-YEAR ASCVD RISK ‡5% THRESHOLD.
When we used an estimated 10-year ASCVD risk $5%
threshold for the primary prevention risk calcula-
tion, 6,608 of our cohort patients (0.6%) moved from
the no risk criteria group to the estimated 10-year
ASCVD risk $5% prevention group. The rates of
lipid-lowering therapies among these groups did
not change signiﬁcantly from the primary analysis
(Figure 6). Among the estimated 10-year ASCVD
risk $5% group, 10,209 eligible patients (37.0%) were
not receiving any lipid-lowering therapy, 1,366 (5.0%)
were receiving nonstatin therapies, 11,114 (40.4%)
were receiving statin therapies, and 4,923 (18.0%)
were receiving both statin and nonstatin therapies.
Among the no risk criteria group, 18,639 eligible pa-
tients (48.7%) were not receiving any lipid-lowering
therapy, 1,671 (4.4%) were receiving nonstatin thera-
pies, 12,808 (34.8%) were receiving statin therapies,
and 5,193 (13.7%) were receiving both statin and
nonstatin therapies.
LDL-C TARGETS <100 MG/DL AND <70 MG/DL. In our
primary cohort, 341,669 eligible patients (29.3%) were
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2189not receiving any lipid-lowering therapies. Among
these patients, 73,604 (21.5%) had an LDL-C assess-
ment, of which 43,097 (12.6%) had an LDL-C value
<100 mg/dl and 7,029 (2.1%) had an LDL-C value <70
mg/dl. Therefore, 12.6% of eligible patients not on
lipid-lowering therapies appeared to be treated in line
with the ATP-3 guidelines.
DISCUSSION
We assessed the potential impact of the new 2013
cholesterol guidelines on current lipid-lowering
treatment and LDL-C testing patterns in a large,
contemporary clinical registry analysis of U.S. cardi-
ology practices (Central Illustration). We demonstrated
that the majority of patients in the PINNACLE registry
qualify for statin therapy under the new guidelines,
primarily for secondary prevention of cardiac events.
However, 32.4% of these patients were not receiving
statin therapy. In addition, 22.6% were receiving
nonstatin therapies, including 3.1% receiving non-
statins as their sole lipid-lowering therapy. Moreover,
repeated LDL-C testing occurred in 20.8% of patients,
which may no longer be needed given the shift away
from a “treat to LDL target” strategy (1). Overall, these
ﬁndings suggest the existence of signiﬁcant gaps in
secondary prevention for contemporary cardiac pa-
tients, and the implementation of the 2013 cholesterol
guidelines will prompt signiﬁcant changes in their
current management.
The ATP III guidelines, published in 2001, focused
on LDL-C cholesterol lowering as a treatment strategy
in managing patients either with or at high risk for
coronary heart disease (4). They did not speciﬁcally
call for statins as a lipid-lowering therapy, and
many clinicians employed multiple nonstatin lipid-
lowering therapies in an attempt to achieve the rec-
ommended LDL-C targets. This “treat to LDL-C
target” strategy also necessitated frequent LDL-C as-
sessments. In 2008, the National Heart, Lung, and
Blood Institute convened the ATP IV to review and
update the cholesterol guidelines to reduce cardio-
vascular risk. In 2013, the full panel transitioned to
the ACC/AHA Expert Panel to complete the guide-
line update (2,3). In accordance with best practices
advocated by the National Heart, Lung, and Blood
Institute Systematic Evidence Review, the panel
considered randomized controlled trials as the most
appropriate source of evidence on which to base their
recommendations (5,6). Only 1 approach to reducing
cardiovascular events through cholesterol treatment,
the use of ﬁxed-dose lipid-lowering drugs, had
been evaluated with randomized controlled trials,
and almost every trial used statin medicationsexclusively. Importantly, none of these trials directly
evaluated the effect of adjusting statin or other
lipid-lowering therapies to achieve speciﬁc LDL-C
targets, but they demonstrated that ﬁxed-dose
statin therapy provides consistent relative risk
reduction among all patient subgroups. Accordingly,
the panel determined that 4 patient risk groups
warranted moderate-dose to high-dose statin ther-
apy: those with ASCVD; diabetes; LDL $190 mg/dl;
and/or a 10-year estimated ASCVD risk $7.5%. The
panel did not ﬁnd evidence to support the use of
nonstatin lipid-lowering therapies (such as ﬁbrates or
niacin), and thus did not recommend their use.
Finally, though the panel indicated that LDL-C as-
sessments should be used to gauge initial ASCVD risk
and could be used to check for patient adherence to
statin therapy, its routine assessment to adjust lipid-
lowering dosing to speciﬁc LDL-C targets is no longer
needed.
These new cholesterol guidelines have signiﬁcant
implications for both cardiac patients and the general
medical population. Using a national sample of
the U.S. population, Pencina et al. (7) found that an
additional 12.8 million U.S. adults (11.1%) ages 40 to
75 years of age would qualify for statin therapy under
these new guidelines. Our ﬁndings complement this
work by examining the implications of the guidelines
for patients seen in U.S. cardiology practices. As
expected, the vast majority of these patients has
conﬁrmed cardiovascular disease and thus is at the
highest risk for recurrent cardiac events. Despite
this need, one-third of these patients were not
currently treated with a statin. Furthermore, almost
80
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CENTRAL ILLUSTRATION Impact of the 2013 ACC/AHA Cholesterol Guidelines on PINNACLE Cardiovascular Practices
(Top) Percentage of patients from NCDR PINNACLE (National Cardiovascular Data Registry Practice Innovation and Clinical Excellence) from 2008 to 2012.
(Bottom) Anticipated changes for PINNACLE patients under the 2013 ACC/AHA Cholesterol Guidelines. ASCVD ¼ atherosclerotic cardiovascular disease;
LDL-C ¼ low-density lipoprotein cholesterol.
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2190one-quarter of patients were receiving nonstatin
lipid-lowering therapies, which are no longer indi-
cated for cardiac event prevention under the new
guidelines. Finally, 20.8% of patients received $2
LDL-C assessments, and 7.0% had $4 assessments,
testing that may no longer be as necessary in a “treat
to risk,” rather than a “treat to LDL-C target” envi-
ronment. The secondary analyses excluding severe
heart failure patients and varying the primary pre-
vention risk threshold for treatment did not signiﬁ-
cantly alter these primary ﬁndings. Given the
controversy surrounding the guideline risk model andits potential for risk overestimation (11,12), it is
particularly important that our ﬁndings were not
signiﬁcantly altered by varying risk thresholds. In
addition, the ﬁnding that 12.6% of patients on no
lipid-lowering therapy had LDL-C values <100 mg/dl
underscores the differences between ATP-3 and
ATP-4 and illustrates how these new guidelines will
expand the indications for statin therapy.
These ﬁndings have several implications for
cardiac patients. As the provider and patient com-
munity move toward adopting these guidelines,
increased statin use, decreased nonstatin use, and
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2191decreasing LDL-C testing are expected. Accordingly,
if the 377,311 eligible patients in the PINNACLE
population not currently receiving statin therapy
receive them as a result of these guideline changes,
then those patients would have a 25% reduction, on
average, in cardiovascular events (13). This beneﬁt
would be especially pronounced among those with
diabetes or an estimated ASCVD risk $7.5%, who
were noted to have the highest rates of nonstatin use
(36.2% and 36.6%, respectively) in this population.
Next, as the number of nonstatin lipid-lowering
therapies is reduced, the side effects of nonstatin
lipid-lowering therapies (especially myopathic
symptoms, which have a higher incidence among
patients treated with both statins and either ﬁbrates
or niacin) would be expected to decline. In addition,
among those patients with no risk criteria, 48.6%
were currently receiving statin therapy, which may
no longer be indicated under the new guidelines.
Finally, the cost and inconvenience of repeated
LDL-C testing to titrate statin medication to speciﬁc
LDL-C targets would be reduced. The overall net cost
effect of the new guidelines is complex, as the cost of
statin use must be considered against the savings
from reduced cardiovascular event occurrence, re-
duced use of nonstatin therapies, reduced use of sta-
tins among patients without indication, and reduced
testing.
STUDY LIMITATIONS. First, the study population is
restricted to cardiology practices that voluntarily
participate in the PINNACLE registry. Therefore, the
patients in our study may have greater cardiovascular
risk and higher lipid-lowering therapy rates than the
general population. In addition, the PINNACLE reg-
istry participating practices may represent providers
with a particular interest in quality improvement ef-
forts. As a result, they may not be representative of all
cardiology or primary care practices in the United
States. However, we demonstrate signiﬁcant oppor-
tunities for optimizing treatment among PINNACLE
practices, suggesting that treatment gaps in the
broader cardiology and general medical communities
may be even larger. Second, the PINNACLE registry
extracts data directly from clinical electronic health
records, and lipid-lowering therapies and lipid panel
assessments may be incompletely captured. How-
ever, PINNACLE conducts periodic data quality as-
sessments to mitigate this potential issue. Third, the
current PINNACLE registry does not contain infor-
mation on statin type or dosing, which could provide
additional insight into expected changes from the
updated guidelines. In addition, renal function data is
not available in the current registry, which preventsus from understanding the number of patients on
hemodialysis who would not qualify for statin ther-
apy. The next version of PINNACLE data will collect
information on both statin type and dosing as well
as renal function, and future analyses will provide
insights into those questions. Fourth, if patients
were prescribed therapies before their index visit
and the electronic medical record failed to carry
those prescriptions forward, the method used to
categorize lipid-lowering therapy for each patient
could have underestimated current lipid-lowering
therapy rates. This misclassiﬁcation would, if any-
thing, result in an even larger gap between current
practice and guideline-concordant care than this
analysis indicates, further underscoring the need for
action. Fifth, LDL-C assessments are often conducted
in venues other than cardiology practices, such as
primary care and neurology practices. As such, the
analysis of repeated LDL-C assessment may under-
estimate the number of repeated assessments.
Finally, many LDL-C levels in the cohort were
measured in the setting of lipid-lowering therapy,
which means that the estimated risk $7.5% patient
risk group may be underestimated and the no risk
criterion groups may be overestimated. This was
partially accounted for in the sensitivity analysis
that reduced the risk threshold to $5% and (as with
the misclassiﬁcation possibility) continues to high-
light that actual practice may have even more sig-
niﬁcant gaps in therapy than are indicated by this
analysis.
CONCLUSIONS
This study found that in U.S. cardiovascular practices
participating in the PINNACLE registry, 32.4% of pa-
tients with an indication for statins under the 2013
ACC/AHA cholesterol guideline were not currently
receiving them. In addition, 22.6% were receiving
nonstatin therapies. Moreover, repeated lipid testing
occurred in 20.8% of patients. Achieving concordance
with the new cholesterol guidelines would result in
signiﬁcant increases in statin use and might also lead
to signiﬁcant reductions in nonstatin therapies and
laboratory testing.
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: The
2013 blood cholesterol guidelines recommend statin
treatment for patients with ASCVD, diabetes, LDL-C
levels $190 mg/dl, or a 10-year ASCVD risk $7.5%.
LDL-C assessments to titrate statin therapy to speciﬁc
LDL-C goals and nonstatin treatments are no longer
recommended.
COMPETENCY IN SYSTEMS-BASED PRACTICE:
Physicians and other healthcare professionals should
examine their cholesterol treatment and testing patterns
to assess alignment with current guidelines.
TRANSLATIONAL OUTLOOK: Clinical outcomes
studies are needed to gauge the effect of application of
blood cholesterol on cardiac events in well-deﬁned prac-
tice-based patient populations.
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